[go: up one dir, main page]

WO2004060075A1 - Agent pour generer une sensation de satiete et faire perdre du poids a des animaux - Google Patents

Agent pour generer une sensation de satiete et faire perdre du poids a des animaux Download PDF

Info

Publication number
WO2004060075A1
WO2004060075A1 PCT/EP2003/014444 EP0314444W WO2004060075A1 WO 2004060075 A1 WO2004060075 A1 WO 2004060075A1 EP 0314444 W EP0314444 W EP 0314444W WO 2004060075 A1 WO2004060075 A1 WO 2004060075A1
Authority
WO
WIPO (PCT)
Prior art keywords
volume
attractant
examples
animals
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/014444
Other languages
German (de)
English (en)
Inventor
Günther Beisel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE20219665U external-priority patent/DE20219665U1/de
Priority claimed from DE10259507A external-priority patent/DE10259507A1/de
Application filed by Individual filed Critical Individual
Priority to AU2003300531A priority Critical patent/AU2003300531A1/en
Publication of WO2004060075A1 publication Critical patent/WO2004060075A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Definitions

  • the present invention relates to a means for producing a satiety effect and for reducing weight in animals, and to a method for its production and its use.
  • a means for oral ingestion which consists of a container which is detachable in the stomach and releases the contents. This is filled with a substance that increases its volume in the stomach after its release, thereby suggesting a feeling of satiety in the body.
  • the disadvantage of this saturant is that there is a risk of intestinal obstructions.
  • the object of the present invention is therefore to provide an agent which is suitable for the treatment of obesity in animals.
  • This object is achieved according to the invention by a means for producing a satiety effect and for reducing weight in animals containing a volume-increasing material which is insoluble or poorly soluble in gastrointestinal fluids and / or body fluids and at least one attractant which is effective for the respective animal species.
  • flavoring agents are primarily considered as attractants.
  • Aroma is a sensory impression that the aroma substances produce.
  • aroma is the overall olfactory impression of volatile substances in a sample. It differs from the smell in that many of the flavoring substances are only released when they are chewed by the warmth of the oral cavity, etc. and then contribute to the sensation via the throat-nose connection.
  • natural and nature-identical aroma substances can be used.
  • heterocyclic compounds are furans, furanones, thiophenes, pyrazines, thiazoles.
  • meat preferably Sausage, cheese and / or yeast flavors. Accordingly, meat, cheese or yeast extracts can be added to the volume-increasing material according to the invention.
  • the attractants can be incorporated into the volume-increasing material. It is also possible to apply the attractants to a volume-increasing material which already contains attractants which have already been incorporated.
  • the attractants can be applied to the surface or to a part of the surface of the volume-increasing material. Suitable adhesion promoters can be used for this.
  • adhesion promoters can be powders, pastes, solutions, melts or foils.
  • a film-shaped adhesion promoter layer can have adhesive properties on both sides and in this way ensure the cohesion of the carrier material with the layer containing the active substance.
  • adhesion promoters preference is given to compounds which contain natural, synthetic and semisynthetic polymers.
  • nonionic and ionic polymers come into consideration.
  • all hot-melt adhesives and contact adhesives known from the prior art can be used, provided they are suitable for pharmaceuticals or food.
  • the adhesion promoter is starch derivatives, cellulose derivatives, gelatin or polysaccherides, preferably polysaccherides containing polyuronic acid, for example polyalginates. Hypomellose, Carmellose, Metholose may be mentioned as examples.
  • Particularly preferred polysaccharides containing poiyuronic acid are alginic acids and their salts (alginates).
  • low-esterified pectins, xanthan, tragacanth, chondroitin sulfate and all other compounds containing uronic acid can also be used according to the invention.
  • the use of thread-like or fabric-like material is also conceivable, by means of which the desired duration of the connection between the carrier material and the active substance-containing layer can be controlled. Accordingly, the invention also relates to an agent containing thread-like and / or fabric-like substances as a connecting agent.
  • formulations containing active ingredients can also be applied to the volume-enlarging material by means of the adhesion promoter described.
  • the agent according to the invention using the adhesion promoters described is split up into volume-enlarged material and the layer (s) containing the active ingredient-containing formulation (s).
  • the active ingredient-containing formulation (s) can therefore enter the intestine, i.e. because of this, be absorbed in the intestine.
  • the material which increases the volume according to the invention ensures that the low-calorie / low-calorie volume increase of the nutritional value required to develop the satiety effect
  • the material is therefore larger than the opening of the stomach outlet and is therefore prevented from being transported quickly from the stomach into the intestine, i.e. the residence time in the stomach for the carrier material is longer than for the layer containing the active substance.
  • the residence time of the carrier material in the stomach a feeling of satiety is created and is maintained for the time it remains in the stomach.
  • the active ingredients are also possible to combine different active ingredients.
  • an adhesive that does not dissolve in the stomach can be used. Active ingredients are then applied to this coupling agent, which are to remain in the stomach and develop their effect there.
  • the adhesive that is soluble in the stomach these pieces of material become detached from one another. As a result, an increased saturation effect can be achieved.
  • the active substances can be arranged between several pieces of material by means of the adhesion promoter. When the individual pieces of material in the stomach fall apart, the layers of active substance detach and reach the intestine to develop their effect there. If necessary. can also be used active ingredients that at least partially dissolve in the stomach and, if necessary, develop their therapeutic effect there.
  • sponge-like materials can preferably be used as void-enlarging materials.
  • such sponge-like materials are to be understood as solid or semi-solid elastic foams which consist of gas-filled, for example polyhedral, cells which are delimited by highly viscous and / or solid cell webs.
  • both naturally occurring sponges, semi-synthetic or synthetically produced sponge-like structures can be used.
  • synthetic sponge-like materials are polyurethanes, polyacrylates, poly (met) acrylic acid derivatives, homo- and copolymers of vinyl acetate.
  • the natural and semisynthetic polymers include cellulose, cellulose ethers or cellulose esters such as cellulose acetate and cellulose acetate phthalate.
  • Examples of natural polymers are polysaccharides such as alginates, tragacanth, xanthan gum, guar gum and their salts and derivatives. The use of chitin and chitin derivatives is possible. In addition, fabrics with a fiber structure such as ski proteins are preferred. B. collagen, keratin, conchagens, fibroin, elastin and chitin are used. They are also stable cross-linked polysaccharides are the subject of the present invention.
  • the sponge-like or shaped structures are produced using methods known per se according to the prior art.
  • a foam can be obtained in the simplest case by blowing in, by beating, shaking, spraying or stirring in the gas atmosphere in question.
  • the foam structure arises due to chemical reactions. For example, by adding blowing agents which decompose at a certain temperature during processing with the formation of gas, or by adding liquid solvents during the polymerization. Foaming takes place either when leaving the extrusion die, i.e. following extrusion or injection molding or in open molds. Hardening takes place under the conditions which are characteristic of the respective chemical compound of the carrier material.
  • volume-enlarging material An essential property of the volume-enlarging material according to the invention is that it is compressible. Finally, when selecting the carrier material, it is essential that it remains swellable without the cell webs being destroyed.
  • the compressed material can, for example, expand two to ten times, preferably four to eight times its volume.
  • the active substance release areas of the material enlarged under physiological conditions are, for example, 15 to 25 cm 2 .
  • the values of the release areas according to the prior art are 0.5 to 1.5 cm 2 .
  • the material is accordingly preferably in compressed form before and / or during ingestion.
  • the agent according to the invention can be present, for example, in the form of tablets, capsules, dragees, as granules or suppositories or other configurations.
  • the agent according to the invention can have a coating as an outer layer. This can be a lacquer layer or other protective layer which facilitates the taking of the agent according to the invention and which only dissolves in the gastrointestinal tract, for example under the influence of the gastric fluid.
  • the volume-enlarging material according to the invention can also be in the form of powder. According to the invention, this can include both finely divided powders, granules, adsorbates and beadlets. Preferably, materials that enlarge the volume can be produced from dried porous gel or foam. Anionic polymers are preferably used as materials.
  • Anionic polymers preferred according to the invention are polysaccharides and here polysaccharides containing polyuronic acid, such as alginic acids and their salts (alginates).
  • polyuronic acid such as alginic acids and their salts (alginates).
  • alginic acids and their salts alginates
  • low-esterified pectins, xanthan, tragacanth, chondroitin sulfate and all other compounds containing uronic acid can also be used according to the invention.
  • synthetic or semi-synthetic cellulose derivatives such as carboxymethyl cellulose or polyacrylicates.
  • the polyuronic acid-containing polysaccharides suitable for use as adhesion promoters are also suitable for the production of the volume-increasing material.
  • Dried gels or foams containing mixtures of anionic polymers preferably the aforementioned anionic polysaccharides, particularly preferably mixtures of polyuronic acid-containing and low-esterified polysaccharides and in particular mixtures containing salts of alginic acid and pectin can be advantageous according to the invention.
  • Alginic acid is a linear polyuronic acid consisting of alternating proportions of D-mannuronic acid and L-guluronic acid, which are linked together by ⁇ -glycosidic bonds, the carboxyl groups not being esterified.
  • One molecule of alginic acid can be composed of about 150-1050 uronic acid units, with the average molecular weight varying in a range of 30-200 kDa.
  • the polysaccharide alginic acid is a component of the cell walls of brown algae.
  • the proportion of alginic acid in the dry mass of algae can make up to 40%.
  • the alginic acid is obtained by alkaline extraction using methods known per se according to the prior art.
  • the resulting powdered alginic acid is therefore purely vegetable and has a high level of biocompatibility. It can absorb 300 times its own weight in water, forming highly viscous solutions.
  • alginic acid forms so-called gels.
  • the formation of alginate gels in the presence of divalent cations, such as calcium or barium, is described in Shapiro I., et al. (Biomaterials, 1997, 18: 583-90).
  • pectins are preferably used as pectins.
  • pectins consist of chains of ⁇ -1,4-glycosidically linked galacturonic acid units, the acid groups of which are 20-80% esterified with methanol.
  • high-esterified (> 50%) and low-esterified ( ⁇ 50%) pectins The moi mass varies between 10-500 kDa.
  • Pectins are obtained by acidic extraction using methods known per se according to the prior art from the inner portions of citrus fruit peel, fruit pulp or sugar beet pulp.
  • the resulting pectins (apple pectin, citrus pectin) are therefore purely vegetable and are highly biocompatible. They can form gels while absorbing water.
  • pectin gels in the presence of divalent cations, such as calcium or barium, is known. Because of its toxicity, the latter is not suitable for use in biomedicine.
  • divalent cations such as calcium or barium
  • calcium gluconate also provides suitable divalent cations. It is also conceivable to use magnesium salts or a mixture of different physiologically harmless divalent cations.
  • pectins according to the invention are advantageously characterized in that pectins have cholesterol-lowering properties. This property is advantageous in the sense of the present invention, since obesity is generally associated with an elevated cholesterol level.
  • the powdery volume-increasing materials can be produced in various ways.
  • one or more carriers can be placed in a mixer or in a fluidized bed reactor, and then the further components can be added.
  • the carriers it is preferably the materials which increase the volume according to the invention.
  • batch or continuous mixers can be used.
  • the carrier material or material that enlarges the volume may be presented together with additives.
  • Classic examples are flight share mixers, cone screw mixers or similar devices.
  • the product can be mixed by moving the entire container. Examples of this are tumble mixers, drum mixers or the like. Another possibility is to use pneumatic mixers.
  • the powdery compositions according to the invention can also be carried out by the processes of the spray formulation.
  • a first step for example, an aqueous solution of a protective colloid, e.g. Gelatin and / or gelatin derivatives, and / or gelatin substitutes with the addition of the volume-increasing materials described above, and a dispersion is first prepared by adding the attractants and active ingredients with stirring, the aqueous solution of the colloid representing the homogeneous phase of the dispersion.
  • a protective colloid e.g. Gelatin and / or gelatin derivatives, and / or gelatin substitutes with the addition of the volume-increasing materials described above
  • a dispersion is first prepared by adding the attractants and active ingredients with stirring, the aqueous solution of the colloid representing the homogeneous phase of the dispersion.
  • Devices in which such spray formulations can be produced are described, for example, in EP 0074050 B1.
  • the production of granules can be achieved in that the volume-increasing substances and / or spray-dried powders as well as attractants and possibly active components and binders as well as additives produce compact granules in a mixer. become.
  • paddle mixers or flight share mixers can be used as mixers.
  • the liquid components can be added in various ways, for example by being dropped or sprayed on, so that a paste-like, sticky mass is formed.
  • the paste-like mass is cut up and compact granules are formed. Very large chunks can be cut using mixing tools and knives and fine powders can be agglomerated.
  • a solution of sodium alginate in water can be prepared and thickened with the addition of calcium salts.
  • a gel or foam can be obtained by incorporating air and possibly adding surfactants.
  • a dry gel or dry foam sponge
  • pectin-containing gels or foams is carried out in an analogous manner, as is the production of gels or foams containing mixtures of anionic polymers.
  • the coating layers which may contain the attractants for the animals, can be added after the production of the powders or granules in mixers at a lower speed of the mixing tools and stationary knives or in a type-related downstream mixer.
  • the agents according to the invention can be shaped by pressing the pasty, sticky phases during the granulation process through the die of an extruder.
  • the dosing or addition of attractants can optionally be carried out together with additives, for example by means of dripping on or spraying out. Examples of this are lances, shower heads, single-substance or multi-substance nozzles, in rare cases rotating dripping or atomizing devices. In the simplest case, addition is also possible locally as a concentrated jet.
  • the attractant can first be placed in the mixer in order to then give up the volume-increasing material.
  • the addition of the attractant can Normal pressure or under vacuum, counter-atmosphere, preferably under normal pressure or vacuum. To increase the loading of the volume-increasing material and to minimize the influence of oxygen, it may be advantageous to evacuate the mixer containing the volume-increasing material before adding the attractant and, if necessary, to cover it with protective gas.
  • the void-enlarging material according to the invention and the attractants used can also contain further auxiliaries, these being applied to the void-enlarging material or attractants and / or incorporated into the void-enlarging material.
  • inorganic or organic calcium salts e.g. Calcium chloride or calcium gluconate
  • magnesium salts is also conceivable, as well as mixtures of different physiologically harmless divalent cations.
  • the addition of salts of physiologically harmless trivalent cations e.g. of soluble aluminum salts.
  • the agents according to the invention can be prepared by adding soluble aluminum salts to an aqueous solution of anionic polymers, preferably alginates and / or pectins, using a manufacturing method of the type described above.
  • Particularly suitable soluble aluminum salts are aluminum chloride or aluminum sulfate.
  • the soluble aluminum salts can be used alone or in combination.
  • salts of divalent cations such as. B. calcium or Magnesium salts or a combination thereof are used in the preparation of the agents according to the invention.
  • auxiliary substances can also be added: Water-insoluble auxiliary substances or mixtures thereof, such as lipids, etc.
  • Fatty alcohols e.g. Cetyl alcohol, stearyl alcohol and cetostearyl alcohol
  • Glycerides e.g. Glycerol monostearate or mixtures of mono-, di- and triglycerides of vegetable oils
  • hydrogenated oils such as hydrogenated castor oil or hydrogenated cottonseed oil
  • Waxes e.g. Beeswax or carnauba wax
  • solid hydrocarbons e.g. Paraffin or earth wax
  • Fatty acids e.g. stearic acid
  • certain cellulose derivatives e.g.
  • Ethyl cellulose or acetyl cellulose Ethyl cellulose or acetyl cellulose; Polymers or copolymers such as polyalkylenes, e.g. Polyethylene, polyvinyl compounds e.g. Polyvinyl chloride or polyvinyl acetate, as well as vinyl chloride-vinyl acetate copolymers and copolymers with crotonic acid, or polymers and copolymers of acrylates and methacrylates, e.g. Copolymers of acrylic acid ester and methacrylic acid methyl ester can be used.
  • polyalkylenes e.g. Polyethylene
  • polyvinyl compounds e.g. Polyvinyl chloride or polyvinyl acetate
  • vinyl chloride-vinyl acetate copolymers and copolymers with crotonic acid or polymers and copolymers of acrylates and methacrylates, e.g. Copolymers of acrylic acid ester and meth
  • the agents according to the present invention can additionally contain fillers, disintegrants, binders and lubricants and carriers which have no decisive influence on the release of active ingredients.
  • examples include bentonite (aluminum oxide-silicon oxide hydrate), silica, cellulose (usually microcrystalline cellulose) or cellulose derivatives, for example methyl cellulose, sodium carboxymethyl cellulose, sugars such as lactose, starches, for example maize starch or derivatives thereof, for example sodium carboxymethyl starch, starch paste, phosphoric acid salts, for example di - or tricalcium phosphate, gelatin, stearic acid or suitable salts thereof, for example magnesium stearate or calcium stearate, talc, colloidal silicon oxide and similar auxiliaries.
  • active ingredients can also be applied to the described volume-enlarging material, preferably using the adhesion promoters described.
  • the active ingredients can be applied directly in combination with the attractants if they have, for example, adhesion-promoting substances or develop adhesive properties under pressure under temperatures.
  • the active ingredients as well as the attractants can be incorporated into the void-enlarging material.
  • Active substance in the sense of the invention means all substances with a pharmaceutical or biological effect.
  • Examples of active substance-containing formulations according to the invention from different therapeutic classes are given below, which, however, are not limiting for the present invention.
  • ACE inhibitors are: benazepril, captopril, cilazapril, enalapril, fosinopril, lisinopril, perinodopril, quinapril, ramipril, trandolopril.
  • analeptics examples include: Aimitrin, Amiphenazol, Caffeine, Doxapram, Etamivan, Fominoben . Metamfetamine, nicethamide, pentetrazole.
  • analgesics opioid are: alfentanil, buprenorphine, cetobemidone, dextromoramide, dextropropoxyphene, fentanyl, flupirtine, hydromorphone, levomethadone, levorphanol, meptazinol, morphine, nalbuphin, oxycodone, pentazocinramid, pethidine.
  • analgesics non-opioids
  • examples of analgesics are: acetylsalicylic acid, benzyl almondate, bucetin, ethenzamide, ketorolac, metamizole, morazone, paracetamol, phenacetin, phenazone, propyphenazone, salicylamide.
  • examples of anthelmintics are: albendazole, diethylcarbamazine, mebendazole, praziquantel, tiabendazole.
  • antiallergics / antihistamines are: anatazoline, astemizole, azelastine, bamipine, brompheniramine, buclizine, carbinoxamine, cetririzine, chlorophenamine, clemastine, cyslizine, cyproheptadine, dimenhydramine, doxylamine, fexofenadine, ketotifen midomolininoxinamin, oximinomolininoxin, oximinomolininoxin, oxaminolominaminolamin, oximinomolamin, oxinate, morphine, loramin, oximinomolamin, oxinate, morphine, oxinate , Pheniramine, phenyltoloxamine, spaglumic acid, terfenadine, triprolidine.
  • antiarrhythmic drugs are: ajmaline, amiodarone, aprindine, quinidine, disopyramide, mexiletine, procainamide, propafenone, tocainide.
  • antibiotics / chemotherapeutics are: Amikacin, Gentamicin, Kanamycin,
  • antidepressants are: amitripytylin, amitriptyline oxide, clomipramine, desipramine, dibenzepine, dosulepin, doxepin, fluoxetine, fluvoyamine, imipramine, lithium salts, maprotiline, nomifensin, opipramol, oxitriptan, tranylcypromine, trimipramine.
  • Examples of antidiabetics / antihypoglycaemics are: acarbose, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidon, glisoxepid, glymidine, guar, insulin, metformin, tolazamide, tolbutamide.
  • antidiarrheals examples include difenoxine, diphenoxylate, loperamide, petin, tannin.
  • antidotes examples include flumazenil, naloxone, naltrexone.
  • antiemetics examples include alizapride, betahistine, thiethylperazine.
  • antiepiieptics are: barbexaclone, carbamazepine, ethosuximide, lamotrigine, mepacrine, mesuximide, phenobarbital, phenytoin, primidone, sultiam, trimethadione, valproic acid, vigabatrin.
  • antifibrinolytics are: aminocaproic acid, 4- (aminomethyl) benzoic acid, tranexamic acid.
  • antihypertensives examples include: clonidine, diazoxide, doxazosin, guanethidine, hydralazine, methyldopa, moxonidine, nitroprusside sodium, phentolamine, prazosin, reserpine, tiamenidine, urapidil.
  • antihypotonic agents dihydroergotamine, dobutamine, dopamine, etilefrin, norepinephrine, norfennefrin.
  • anticoagulants are: acenocoumarol, sodium dalteparin, enoxaparin, heparin, heparinoids hirudin, lepirudin, nadroparin, parnaparin, phenprocoumon, reviparin, tinzaparin, warfarin.
  • antifungals examples include amorolfine, amphotericin B, bifonazole, chlormidazole, ciclopiroxolamine, clotrimazole, croconazole, econazole, fenticonalzol, fluconazole, griseofulvin, isoconazole, itraconazole, tioconazole, oxifazonazole, miconazonazole, miconazonazole, tolnaftate.
  • antirheumatic agents are: acemetacin, azapropazon, benorilat, bumadizon, carprofen, choline salicylate, diclofenac, diflunisal, etofenamate, felbinac, fenbufen, fenoprofen, fiufenamic acid, flurbiprofen, ibuprofen, indomofamebamolamone, melonacidamonamone, melonacidamonamone, melonacidamonamone, melonacidamonamone, melonacidamonacid , naproxen, nifenazone, niflumic, oxyphenbutazone, phenylbutazone, piroxicam, pirprofen, proglumetacin, Pyrazinobutazon, salsalate, sulindac, suxibuzone, tenoxicam, tiaprofenic acid, tolmet
  • antitussives examples include benproperin, butamirate, butetamate, clobutinol, clofedanol, codeine, dextromethorphan, dihydrocodeine, hydrocodone, isoaminil, sodium dibunate, noscapine, oxeladine, pentoxyverine, pholcodine, pipacetate.
  • appetite suppressants are: Amfepramon, Fenfluramin, Fenproporex, Levopropylhexedrin, Mazindol, Mefenorex, Metamfepramon, Norephedrin, Norpseudoephedrin.
  • beta-adrenergic blockers are: Acebutolol, Alprenolol, Atenolol, Betaxolol, Bisoprolol, Bopindolol, Bupranolol, Carvedilol, Celiprolol, Labetalol, Levobunolol, Mepindolol, Metipranolol, Metoprolol, Nadolol, Oxprenolol, Poleololol, Oxprenolol, Poleololol.
  • bronchospasmolytics / antiasthmatics are: bambuterol, carbuterol, clenbuterol, epinephrine, fenoterol, hexoprenaline,
  • calcium antagonists examples include amlodipine, felodipine, isradipine, nicardipine, nifedipine, nilvadipine, nitrendipine, nisoldipine, verapamil.
  • cholagoga examples include anethole trithione, azintamide, chenodeoxycholic acid, dehydrocholic acid, hymecromone, piprozoline, ursodeoxycholic acid.
  • cholinergics / cholinoiytics examples include: aceclidine, acetylocholine, carbachol, cyclopentolate, distigmine, edrophonium, emepronium, homatropin, methantheline, neostigmine, pilocarpine, propantheline, propiverine, pyridostigmine, tropicamide.
  • diuretics examples include: acetazolamide, amiloride, bendroflumethiazide, bumetanide, chlorothiazide, chlortalidone, clopamide, etacrynic acid, furosemide, hydrochlorothiazide, triamterene, xipamide.
  • agents which promote blood circulation / nootropics are: buflomedil, buphenin, dextran 40, dihydroergotoxin, lloprost, meclofenoxate, Nicergoline, nicotinic acid, pentifylline, piracetam, piribedil, pyritinol, tolazoline, viquidil.
  • enzymes / inhibitors / transport proteins are: antithrombin III, aprotinin, carnitine, clavulanic acid, dornase alfa, sulbactan.
  • expectorants are: acetylcysteine, ambroxol, bromhexine, carbocistein, colfosceril, surfactant (from beef liver), surfactant (from pork lungs).
  • gout agents are: allopurinol, benzbromaron, colchicine, sample oath, sulfinpyrazone.
  • glucocorticoids examples include betamethasone, budesonide, cloprednol, cortisone, dexamethasone, flunisolide, fluticasone, hydrocortisone, methylprednisolone, paramethasone, prednisolone, prednisone, prednylidene, triamcinolone.
  • hemostyptics are: Adrealon, blood coagulation factor VII, blood coagulation factor VIII, blood coagulation factor IX, blood coagulation factor XIII, carbazochrome, etamsylate, fibrinogen, collagen, menadiol, menadione, protamine, somatostain, thrombin, thromboplastin.
  • pituitary / hypothalamic hormones and inhibitors examples include: Argipressin, Chorionic Gonadotrophin, Desmopressin, Felypressin, Gonadorelin, Lypressin, Menotropin, Ornipressin, Quinagolid, Terlipressin, Thyrotrophin.
  • immunotherapeutics and cytokines are: aldesleukin, azathioprine, BCG, ciciosporin, filgrastim, interferon alfa, interferon beta, Interleukin-2, Muromonab-CD3, Tacrolism, Thymopentin,
  • Kardiaka examples of Kardiaka are: Acetyldigitoxin, Acetylödiagoxin, Convallatoxin, Digitoxin, Digoxin, Gitoformat, Lanatosid, Meproscillarin, Metildigoxin, Pengitoxin, Peruvosid, Proscillaridin, Strophanthin, Thevetin, Amrinon, Enoximon, Milrinon
  • coronary agents are: carbocromes, isosorbide dinitrate, nitroglycerin, pentaerythrityl tetranitrate.
  • Laxantia examples include bisacodyl, Dantron, docusate, glycerol, lactulose, magnesium sulfate, sodium picosulfate, sodium sulfate, Paraffinum subüqiudum, phenolphthalein, castor oil, sorbitol.
  • liver therapeutic agents are: choline, citiolon, myo-inositol, silymarin.
  • lipid-lowering agents examples include: acipimox, bezafibrate, clofibrate, etofibrate, fluvastin, lovastatin, pravastatin, simvastin.
  • Examples of local anesthetics are: Articaine, Benzocaine, Bupivacaine, Butanilicain, Chloroethane, Cinchocaine, Cocaine, Etidocaine, Fomocaine, Lidocaine, Mepivacaine, Myrtecain, Oxetacaine, Oxybuprocaine, Polidocanol, Prilocaine, Procaine, Proxymainocaine, Quaincaine.
  • gastrointestinal agents are: bismuth subcitrate, bromopride, garbenoxolone, cimetidine, domperidone, famotidine, metoclopramide, nizatidine, omeprazole, proglumid, ranitidine, roxatidine, sucralfate, sulfasalazine.
  • migraine drugs are: Ergotamine, Lisurid, Naratriptan, Pizotifen, Sumatriptan, Zolmitriptan.
  • muscle relaxants are: Alcuronium, Atracurium, Baclofen, Carisoprodol, Chlormezanon, Clostridium toxin botulinum toxin A,
  • parathyroid therapeutics / calcium metabolism regulators examples include clodronic acid, dihydrotachysterol, parathyroid glands, pamidronic acid.
  • neuroleptics are: Benperidol, Chlorpromazin, Droperidol, Klieanzin, Haloperidol, Melperon, Promethazin, Zuclopenthixol.
  • Parkinson's agents are: amantadine, benserazide, benzatropine, biperiden, bornaprine, bromocriptine, cabergoline, carbidopa, diphydroergocriptine, levodopa, metixen, pergolide, pramipexole, ropinirole, tolcapone.
  • psychostimulants are: Amfetaminil, Deanol, Fencamfamin, Fenetyllin, Kavain, Methylphenidat, Pemolin, Prolintan.
  • thyroid therapeutics are: carbimazole, thyroid gland, iodine, iodide, levothyroxine, liothyronine, methylthiouracil, perchlorate, prolonium iodide, propylthiouracil, radio iodine, thiamazole.
  • Examples of sedatives / hypnotics are: amobarbital, chloral hydrate, clomethiazole, glutethimide, hexobarbital, methaqualon, methyprylon, pentobarbital, scopolamine, secbutabarbital, secobarbital, vinylbital, zolpidem, zopiclone.
  • sex hormones are: chlorotrianisen, clomiphene, clostebol, cyproterone, drostanolone, epimestrol, estradiol, estriol, estrone, ethinylestradiol, flutamide, fosfestrol, conjugated estrogens, medroxyprogesterone, mesterolone, mestranol, oxestronolone, methylolonolone, methylstrol Stanozolol, testosterone.
  • spasmolytics are: atropine, butylscopolamine, flavoxate, glycopyrronium, mebeverine, methylscopolamine, oxybutynin, tiropramide, trospiun.
  • platelet aggregation inhibitors examples include abciximab, acetylsalicylic acid, dipyridamole, ticlopidine.
  • transquilizers are: Alprazolam, Bromazepam, Brotizolam, Buspiron, Camazepam, Chlordiazepoxid, Clobazam, Clonazepam, Clorazepat, Clotiazepam, Diazepam, Flunitrazepam, Flurazepam, Hydroxyzin, Ketazolam, Loprazolam, Lorazepamzepam, Lorazepamepam, Lorazepamepam , Oxazepam, oxazolam, prazepam, temazepam, tetrazepam, triazolam.
  • urologicals examples are: finasteride.
  • varia examples include dapiprazole, diethyltoluamide, lipoic acid.
  • venous agents examples include aescin, calcium dobesilat, coumarin, diosmin, rutoside, troxerutin.
  • antivirals examples include: acyclovir, cidofovir, didanosine, famciclovir, foscarnet, ganciclovir, lamivudine, ritonavir, zalcitabine, zidovudine.
  • vitamins are: alfacalcidol, allithiamine, ascorbic acid, biotin, calcifediol, calcitriol, colecalciferol, cyanocobalamin, ergocalciferol, folic acid, hydroxocobalamin, nicotinamide,
  • Pantothenic acid phytomenadione, pyridoxine, retinol, riboflavin, thiamine, tocopherol, transcalcifediol.
  • cytostatics are: aclarubicin, altretamine, aminoglutethimide, amsacrine, asparaginase, bleomycin, buserelin, busulfan, carboplatin.Carmustin, chlorambucil, cladribine, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorbesicin, eparodinubidolin, duborodinubidolin, duborodinodinolubidolin, duborodinodinolubidol, duborodinodinodinubidolin, duborodicin, dodorodicin, dodorodicin, dodorodicin, dodorodicin , Fluorouracil, gemcitabine, goserelin, hydroxycarbamide, idarubicin, ifosfamide, lomustine, melphalan, mercaptopurine, mesna, methotre
  • the active substances mentioned can be present in the form of a powder, a paste, a film, as a solution or as a melt and can be applied to the volume-enlarging material, preferably using the adhesion promoters described above.
  • the active ingredients described can also be incorporated into the volume-enlarging material. U.U.
  • a sustained release of active ingredient can be achieved here.
  • the attractants, active ingredients and auxiliaries described can in principle be applied in any combination or incorporated into the surface of the volume-increasing material, depending on the desired end product.
  • the means according to the invention can accordingly be designed in the form of a volume-increasing material, in which only Attractants introduced or on which only attractants are applied.
  • Active ingredients can also be applied or incorporated for medical purposes.
  • the active substances described in more detail above are preferably suitable for this. Instead of the active substances or in addition to these, further auxiliary substances can also be present. These are in particular the auxiliaries described above. Likewise, any nutrients such as vitamins or trace elements can be involved.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un agent destiné à générer une sensation de satiété et à faire perdre du poids à des animaux, ainsi qu'un procédé de production associé et l'utilisation de cet agent chez des animaux.cet agent contient une matière non soluble ou difficilement soluble dans les liquides gastro-intestinaux et/ou biologiques qui augmente de volume et une substance attirant le type d'animal considéré.
PCT/EP2003/014444 2002-12-19 2003-12-18 Agent pour generer une sensation de satiete et faire perdre du poids a des animaux Ceased WO2004060075A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003300531A AU2003300531A1 (en) 2002-12-19 2003-12-18 Substance for creating a saturation effect and reducing weight in animals

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE20219665.8 2002-12-19
DE20219665U DE20219665U1 (de) 2002-12-19 2002-12-19 Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung bei Tieren
DE10259507A DE10259507A1 (de) 2002-12-19 2002-12-19 Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung bei Tieren
DE10259507.0 2002-12-19

Publications (1)

Publication Number Publication Date
WO2004060075A1 true WO2004060075A1 (fr) 2004-07-22

Family

ID=32714757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/014444 Ceased WO2004060075A1 (fr) 2002-12-19 2003-12-18 Agent pour generer une sensation de satiete et faire perdre du poids a des animaux

Country Status (2)

Country Link
AU (1) AU2003300531A1 (fr)
WO (1) WO2004060075A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108684938A (zh) * 2018-04-16 2018-10-23 广州智特奇生物科技股份有限公司 一种植物精油包被液、微胶囊植物精油及其制备方法
CN118000354A (zh) * 2024-03-13 2024-05-10 重庆汉佩生物科技有限公司 一种宠物高膨胀性体重控制产品及宠物粮食组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892748A (en) * 1988-06-20 1990-01-09 David Piatt & Associates Low calorie pet treat
EP1120046A1 (fr) * 1998-10-09 2001-08-01 Nihon Shokuhin Kako Co., Ltd. Aliments pour animaux de compagnie
US20010018067A1 (en) * 1999-02-23 2001-08-30 Sunvold Gregory D. Use of carbohydrate source to limit weight gain in cats
WO2002000042A2 (fr) * 2000-06-26 2002-01-03 The Procter & Gamble Company Compositions et procedes de regulation du poids corporel
DE20206521U1 (de) * 2002-03-30 2002-08-14 Beisel, Günther, 40789 Monheim Zubereitung zur Appetitminderung, Sättigung und/oder Gewichtsreduktion
DE10161986A1 (de) * 2001-12-17 2003-07-03 Guenther Beisel Mittel zur oralen Einnahme und Verfahren zu dessen Herstellung

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892748A (en) * 1988-06-20 1990-01-09 David Piatt & Associates Low calorie pet treat
EP1120046A1 (fr) * 1998-10-09 2001-08-01 Nihon Shokuhin Kako Co., Ltd. Aliments pour animaux de compagnie
US20010018067A1 (en) * 1999-02-23 2001-08-30 Sunvold Gregory D. Use of carbohydrate source to limit weight gain in cats
WO2002000042A2 (fr) * 2000-06-26 2002-01-03 The Procter & Gamble Company Compositions et procedes de regulation du poids corporel
DE10161986A1 (de) * 2001-12-17 2003-07-03 Guenther Beisel Mittel zur oralen Einnahme und Verfahren zu dessen Herstellung
DE20206521U1 (de) * 2002-03-30 2002-08-14 Beisel, Günther, 40789 Monheim Zubereitung zur Appetitminderung, Sättigung und/oder Gewichtsreduktion

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108684938A (zh) * 2018-04-16 2018-10-23 广州智特奇生物科技股份有限公司 一种植物精油包被液、微胶囊植物精油及其制备方法
CN118000354A (zh) * 2024-03-13 2024-05-10 重庆汉佩生物科技有限公司 一种宠物高膨胀性体重控制产品及宠物粮食组合物

Also Published As

Publication number Publication date
AU2003300531A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
EP2387391B1 (fr) Procédé pour mettre au point une composition liquide à appliquer sous forme de mousse sur la peau et composition pour application topique
DE60319099T2 (de) Kaugummiformulierung und verfahren zur herstellung derselben
DE102005005446A1 (de) Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE69119217T2 (de) Zusammensetzungen zur kontrollierten freigabe
CN101919822B (zh) 综合性能改善的片剂及其制备方法
EP1572238A1 (fr) Agent a liberation retardee de substances
DE10016356B4 (de) Mittel mit verbesserter Retardwirkung und Verfahren zu dessen Herstellung
EP1209988B1 (fr) Substance reticulee servant a produire un effet rassasiant durable et procede de production correspondant
WO2004060075A1 (fr) Agent pour generer une sensation de satiete et faire perdre du poids a des animaux
DE20119843U1 (de) Mittel zur Behandlung von Übergewicht und weiteren Symptomen
DE10259507A1 (de) Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung bei Tieren
DE20219665U1 (de) Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung bei Tieren
DE10259508A1 (de) Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung
WO2004056209A1 (fr) Agent contenant du ginseng destine a la creation d'un effet de satiete et a la reduction de poids
EP1450763B1 (fr) Agent pour traiter la surcharge ponderale en association avec d'autres indications
DE20219657U1 (de) Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung
DE10259509A1 (de) Mittel mit retardierter Stofffreisetzung
DE19942417A1 (de) Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts und Verfahren zu dessen Herstellung
DE20219658U1 (de) Mittel mit retardierter Stofffreisetzung
DE20218682U1 (de) Mittel zur Behandlung von Übergewicht in Kombination mit weiteren Indikationen
DE10258992A1 (de) Auflage für die dematologische und kosmetische Verwendung
EP1136067A1 (fr) Formulations de médicament, administrées par voie orale
WO2018005518A1 (fr) Préparation pharmaceutique pour l'administration de peptides et de protéines
DE20219666U1 (de) Auflage für die dermatologische und kosmetische Verwendung
DE29915656U1 (de) Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP